semaglutide and mthfr GLP-1 agonist reduced diabetes risk (HbA1c) weight (20 lb) in new RCT of people with #schizophrenia, prediabetes, and obesity: Scientific Poster: Resmetirom and Semaglutide
Description
Interesting data from the @EliLillyandCo phase 3 results on retatrutide
Journal of Obesity & Metabolic Syndrome
Unlike some medications that require a gradual taper, GLP-1 receptor agonists can be stopped without a weaning period, though your provider may recommend a follow-up appointment to discuss any withdrawal effects and adjust your care plan
Our experts design a regimen that fits your requirements, ensuring you receive the proper nutrients and physical activity tailored to your bodys needs
